Cadrenal Therapeutics (CVKD) Lytham Partners Spring 2026 Investor Conference summary

Company overview and disease focus

• Focuses on novel therapies for life-threatening immune and thrombotic conditions, with lead program CAD-1005 targeting heparin-induced thrombocytopenia (HIT).

• HIT is a rare but devastating immune-mediated thrombotic disorder, affecting 0.5–1% of patients receiving heparin, with up to 20% mortality.

• HIT leads to severe complications such as strokes, heart attacks, amputations, and increased hospital costs.

Current treatment landscape and unmet need

• Standard HIT therapy uses non-heparin anticoagulants, but these only address complications after they occur.

• Existing treatments do not sufficiently prevent devastating outcomes, highlighting a significant unmet need.

CAD-1005 mechanism and differentiation

• CAD-1005 is a selective 12-LOX inhibitor that interrupts the immune-mediated platelet activation central to HIT.

• Targets the upstream cause of HIT, potentially breaking the cycle of platelet activation and thrombosis.

• Demonstrates selectivity without off-target effects or increased bleeding risk.